1. Home
  2. STKE vs MGNX Comparison

STKE vs MGNX Comparison

Compare STKE & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STKE
  • MGNX
  • Stock Information
  • Founded
  • STKE 2002
  • MGNX 2000
  • Country
  • STKE Canada
  • MGNX United States
  • Employees
  • STKE N/A
  • MGNX N/A
  • Industry
  • STKE
  • MGNX Biotechnology: Pharmaceutical Preparations
  • Sector
  • STKE
  • MGNX Health Care
  • Exchange
  • STKE Nasdaq
  • MGNX Nasdaq
  • Market Cap
  • STKE 95.8M
  • MGNX 99.7M
  • IPO Year
  • STKE N/A
  • MGNX 2013
  • Fundamental
  • Price
  • STKE $3.78
  • MGNX $1.91
  • Analyst Decision
  • STKE
  • MGNX Hold
  • Analyst Count
  • STKE 0
  • MGNX 6
  • Target Price
  • STKE N/A
  • MGNX $3.20
  • AVG Volume (30 Days)
  • STKE 807.3K
  • MGNX 736.8K
  • Earning Date
  • STKE 01-29-2026
  • MGNX 11-04-2025
  • Dividend Yield
  • STKE N/A
  • MGNX N/A
  • EPS Growth
  • STKE N/A
  • MGNX N/A
  • EPS
  • STKE N/A
  • MGNX N/A
  • Revenue
  • STKE $14,342,517.00
  • MGNX $165,495,000.00
  • Revenue This Year
  • STKE $43.15
  • MGNX N/A
  • Revenue Next Year
  • STKE $39.60
  • MGNX N/A
  • P/E Ratio
  • STKE N/A
  • MGNX N/A
  • Revenue Growth
  • STKE N/A
  • MGNX 303.47
  • 52 Week Low
  • STKE $3.06
  • MGNX $0.99
  • 52 Week High
  • STKE $34.32
  • MGNX $5.10
  • Technical
  • Relative Strength Index (RSI)
  • STKE N/A
  • MGNX 57.70
  • Support Level
  • STKE N/A
  • MGNX $1.82
  • Resistance Level
  • STKE N/A
  • MGNX $1.94
  • Average True Range (ATR)
  • STKE 0.00
  • MGNX 0.13
  • MACD
  • STKE 0.00
  • MGNX 0.02
  • Stochastic Oscillator
  • STKE 0.00
  • MGNX 55.93

About STKE Sol Strategies Inc. Common Shares

Sol Strategies Inc is engaged in investing in blockchain technologies and crypto currencies. Company executes its Investment Objective through three lines of effort: Treasury management: Maintaining a core portfolio of cryptocurrencies for long-term growth, enhanced with risk management strategies to minimize volatility, and generating yield through lending, staking, and liquidity provisioning; Private equity focused on early stage companies in the DeFi and blockchain sectors; and Active investments to generate yield through strategic activities, including Bitcoin mining and stalking and validating Solana.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: